| Literature DB >> 30803894 |
Manuel Johanns1, Samanta Kviklyte1, Sheng-Ju Chuang1, Katrien Corbeels2, Roxane Jacobs1, Gaëtan Herinckx1, Didier Vertommen1, Olivier Schakman3, Thibaut Duparc4, Patrice D Cani4, Caroline Bouzin5, Harriet Andersén6, Mohammad Bohlooly-Y6, Bart Van der Schueren2, Jan Oscarsson6, Mark H Rider7.
Abstract
We previously investigated whether inhibition of AMP-metabolizing enzymes could enhance AMP-activated protein kinase (AMPK) activation in skeletal muscle for the treatment of type 2 diabetes. Soluble 5'-nucleotidase II (NT5C2) hydrolyzes IMP and its inhibition could potentially lead to a rise in AMP to activate AMPK. In the present study, we investigated effects of NT5C2 deletion in mice fed a normal-chow diet (NCD) or a high-fat diet (HFD). On a NCD, NT5C2 deletion did not result in any striking metabolic phenotype. On a HFD however, NT5C2 knockout (NT5C2-/-) mice displayed reduced body/fat weight gain, improved glucose tolerance, reduced plasma insulin, triglyceride and uric acid levels compared with wild-type (WT) mice. There was a tendency towards smaller and fewer adipocytes in epididymal fat from NT5C2-/- mice compared to WT mice, consistent with a reduction in triglyceride content. Differences in fat mass under HFD could not be explained by changes in mRNA expression profiles of epididymal fat from WT versus NT5C2-/- mice. However, rates of lipolysis tended to increase in epididymal fat pads from NT5C2-/- versus WT mice, which might explain reduced fat mass. In incubated skeletal muscles, insulin-stimulated glucose uptake and associated signalling were enhanced in NT5C2-/- versus WT mice on HFD, which might contribute towards improved glycemic control. In summary, NT5C2 deletion in mice protects against HFD-induced weight gain, adiposity, insulin resistance and associated hyperglycemia.Entities:
Keywords: AMPK; CN-II; Fat mass; Glucose metabolism; High-fat diet; NT5C2; Soluble 5′-nucleotidase II; Type 2 diabetes
Mesh:
Substances:
Year: 2019 PMID: 30803894 DOI: 10.1016/j.ymgme.2019.01.017
Source DB: PubMed Journal: Mol Genet Metab ISSN: 1096-7192 Impact factor: 4.797